{"related:oXGnyKBuBeUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Sunitinib in patients with metastatic renal cell carcinoma","url":"https://jamanetwork.com/journals/jama/article-abstract/202955","authors":["RJ Motzer","RJ Motzer BI Rini","RJ Motzer BI Rini RM Bukowski","RJ Motzer BI Rini RM Bukowski BD Curti","RJ Motzer BI Rini RM Bukowski BD Curti DJ George…"],"year":2006,"numCitations":1471,"pdf":"https://jamanetwork.com/journals/jama/articlepdf/202955/jpc60004.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16502718046409290145&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:oXGnyKBuBeUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16502718046409290145&hl=en&as_sdt=0,5","publication":"jamanetwork.com","p":1,"exp":1596876833737},{"title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2005.02.2574","authors":["RJ Motzer","RJ Motzer MD Michaelson","RJ Motzer MD Michaelson BG Redman…"],"year":2006,"numCitations":1986,"pdf":"/scholar?output=instlink&q=info:MS-2CTao5YcJ:scholar.google.com/&hl=en&as_sdt=0,5&scillfp=15423635811831188084&oi=lle","citationUrl":"http://scholar.google.com/scholar?cites=9792417914831646513&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:MS-2CTao5YcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9792417914831646513&hl=en&as_sdt=0,5","publication":"ascopubs.org"},{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2007,"numCitations":6133,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","citationUrl":"http://scholar.google.com/scholar?cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NAM1m4X25K8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12674526305022444340&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","url":"ftp://ftp.biostat.wisc.edu/pub/chappell/641/notes.week13and14/JCO-2006-Ratain-2505-12.pdf","authors":["MJ Ratain","MJ Ratain TIM Eisen","MJ Ratain TIM Eisen WM Stadler…"],"year":2006,"numCitations":1225,"pdf":"ftp://ftp.biostat.wisc.edu/pub/chappell/641/notes.week13and14/JCO-2006-Ratain-2505-12.pdf","citationUrl":"http://scholar.google.com/scholar?cites=11052430021036642189&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:jY_AvIseYpkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11052430021036642189&hl=en&as_sdt=0,5","publication":"biostat.wisc.edu"},{"title":"Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients","url":"https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1442-2042.2012.03204.x","authors":["B Neri","B Neri A Vannini","B Neri A Vannini M Brugia","B Neri A Vannini M Brugia A Muto…"],"year":2013,"numCitations":49,"pdf":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1442-2042.2012.03204.x","citationUrl":"http://scholar.google.com/scholar?cites=10283910829438301675&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:63V2smnKt44J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10283910829438301675&hl=en&as_sdt=0,5","publication":"Wiley Online Library"},{"title":"Sorafenib in advanced clear-cell renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","authors":["B Escudier","B Escudier T Eisen","B Escudier T Eisen WM Stadler…"],"year":2007,"numCitations":5345,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","citationUrl":"http://scholar.google.com/scholar?cites=4193023401754303534&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Lhx3fJGcMDoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4193023401754303534&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa021491","authors":["JC Yang","JC Yang L Haworth","JC Yang L Haworth RM Sherry","JC Yang L Haworth RM Sherry P Hwu…"],"year":2003,"numCitations":3244,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa021491","citationUrl":"http://scholar.google.com/scholar?cites=15259092479126344060&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fBEpfcMvw9MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15259092479126344060&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","url":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.997.6153&rep=rep1&type=pdf","authors":["S Faivre","S Faivre C Delbaldo","S Faivre C Delbaldo K Vera","S Faivre C Delbaldo K Vera C Robert…"],"year":2006,"numCitations":1258,"pdf":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.997.6153&rep=rep1&type=pdf","citationUrl":"http://scholar.google.com/scholar?cites=11982878484495275394&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ghUDX368S6YJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11982878484495275394&hl=en&as_sdt=0,5","publication":"Citeseer"},{"title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","url":"http://pfizerpro.com.s3.amazonaws.com/fixtures/oncology/docs/interferon.pdf","authors":["RJ Motzer","RJ Motzer J Bacik","RJ Motzer J Bacik BA Murphy…"],"year":2002,"numCitations":1668,"pdf":"http://pfizerpro.com.s3.amazonaws.com/fixtures/oncology/docs/interferon.pdf","citationUrl":"http://scholar.google.com/scholar?cites=17893470937361497551&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:zz01jANhUvgJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17893470937361497551&hl=en&as_sdt=0,5","publication":"pfizerpro.com.s3.amazonaws.com"},{"title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2004.08.185","authors":["MB Atkins","MB Atkins M Hidalgo","MB Atkins M Hidalgo WM Stadler","MB Atkins M Hidalgo WM Stadler TF Logan…"],"year":2004,"numCitations":1113,"pdf":"/scholar?output=instlink&q=info:xyjnWZHjGXIJ:scholar.google.com/&hl=en&as_sdt=0,5&scillfp=205136760801941013&oi=lle","citationUrl":"http://scholar.google.com/scholar?cites=8221852808159635655&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xyjnWZHjGXIJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8221852808159635655&hl=en&as_sdt=0,5","publication":"ascopubs.org"}]}